评估西格列汀在老年参与者中的安全性:来自西格列汀心血管结局评估试验(TECOS)的分析
TECOS试验是一项随机双盲安慰剂对照研究,评估西格列汀对2型糖尿病合并心血管疾病患者主要复合心血管结局的影响。本文分析≥75岁参与者的基线特征与临床结局,发现老年患者主要结局、死亡、严重低血糖和骨折发生率更高,但西格列汀对心血管风险无显著影响,未提出新的安全性问题。
要点
- ≥75岁参与者占14%,主要结局发生率6.46 vs 3.67事件/100人年,风险比1.72。
- 老年队列中,西格列汀对主要复合结局无显著影响(HR 1.10,95%CI 0.89-1.36)。
- 西格列汀未显著增加死亡、心衰住院、严重低血糖、急性胰腺炎或胰腺癌风险。
核心结论
- 在血糖控制良好且合并心血管疾病的老年2型糖尿病患者中,西格列汀对心血管风险呈中性效应,未提出显著安全性问题。
研究设计与样本
- TECOS为随机、双盲、安慰剂对照试验,纳入2型糖尿病(HbA1c≥6.5%且≤8.0%)合并心血管疾病患者,本文分析其中年龄≥75岁的参与者。
- 共14,351例记录年龄的参与者中,2,004例(14%)年龄≥75岁,平均年龄78.3岁(SD 3.1),男性占68%,2型糖尿病病程中位数12.0年(IQR 7,21)。
主要发现
- 中位随访2.9年期间,老年参与者主要结局发生率为6.46 vs 3.67事件/100人年(风险比1.72,95%CI 1.52-1.94),死亡风险比2.52(95%CI 2.20-2.89),严重低血糖风险比1.53(95%CI 1.15-2.03),骨折风险比1.84(95%CI 1.44-2.35)。
- 老年队列中,西格列汀对主要复合结局无显著影响(HR 1.10,95%CI 0.89-1.36),对死亡(HR 1.05,95%CI 0.83-1.32)、心力衰竭住院(HR 0.99,95%CI 0.65-1.49)、严重低血糖(HR 1.03,95%CI 0.62-1.71)、急性胰腺炎和胰腺癌发生率及严重不良事件均无显著影响。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Limited data exist regarding safety and efficacy of antihyperglycemic drugs in older patients with type 2 diabetes. The Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) was a randomized, double-blind, placebo-controlled trial assessing the impact of sitagliptin on a primary composite outcome of cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, or unstable angina hospitalizations in patients with type 2 diabetes (HbA1c ≥6.5% [48 mmol/mol] and ≤8.0% [64 mmol/mol]) and cardiovascular disease. We analyzed baseline characteristics and clinical outcomes for TECOS participants aged ≥75 years. RESEARCH DESIGN AND METHODS: Clinical and safety event summaries are presented for older versus younger participants and for the treatment groups within the older cohort. RESULTS: Of 14,351 participants with age recorded, 2,004 (14%) were ≥75 years old (mean age 78.3 years [SD 3.1]), with 68% men and type 2 diabetes duration median 12.0 years (IQR 7, 21). During 2.9 years median follow-up, older participants had higher rates of the primary outcome (6.46 vs. 3.67 events per 100 person-years; hazard ratio 1.72 [95% CI 1.52-1.94]), death (2.52 [2.20-2.89]), severe hypoglycemia (1.53 [1.15-2.03]), and fractures (1.84 [1.44-2.35]). In the older cohort, sitagliptin did not significantly impact the primary composite (1.10 [0.89-1.36]), death (1.05 [0.83-1.32]), heart failure hospitalization (0.99 [0.65-1.49]), severe hypoglycemia (1.03 [0.62-1.71]), rates of acute pancreatitis and pancreatic cancer, or serious adverse events. CONCLUSIONS: Among older patients with well-controlled type 2 diabetes and cardiovascular disease, sitagliptin had neutral effects on cardiovascular risk and raised no significant safety concerns.
引用
- Bethel MA, Engel SS, Green JB, et al. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Care. 2017. PMID: 28057693. doi:10.2337/dc16-1135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。